14.91
前日終値:
$14.55
開ける:
$14.765
24時間の取引高:
620.74K
Relative Volume:
0.34
時価総額:
$1.78B
収益:
$59.61M
当期純損益:
$-262.14M
株価収益率:
-3.8036
EPS:
-3.92
ネットキャッシュフロー:
$-247.49M
1週間 パフォーマンス:
-3.37%
1か月 パフォーマンス:
+3.54%
6か月 パフォーマンス:
+9.63%
1年 パフォーマンス:
+46.18%
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
名前
Arcutis Biotherapeutics Inc
セクター
電話
805-418-5006
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ARQT
Arcutis Biotherapeutics Inc
|
14.91 | 1.73B | 59.61M | -262.14M | -247.49M | -3.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-30 | 開始されました | H.C. Wainwright | Buy |
2024-08-28 | 開始されました | Jefferies | Buy |
2024-01-03 | アップグレード | Mizuho | Neutral → Buy |
2023-10-26 | ダウングレード | Mizuho | Buy → Neutral |
2023-10-13 | ダウングレード | Goldman | Buy → Neutral |
2022-09-07 | 開始されました | Needham | Buy |
2022-03-17 | 開始されました | Goldman | Buy |
2021-06-30 | 開始されました | Mizuho | Buy |
2021-05-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-11-09 | アップグレード | Goldman | Neutral → Buy |
2020-10-08 | 開始されました | Truist | Buy |
2020-02-25 | 開始されました | Cantor Fitzgerald | Overweight |
2020-02-25 | 開始されました | Cowen | Outperform |
2020-02-25 | 開始されました | Goldman | Neutral |
2020-02-25 | 開始されました | Guggenheim | Buy |
すべてを表示
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - The Manila Times
What analysts say about Arcutis Biotherapeutics Inc. stockFree Investment Community - Autocar Professional
Arcutis Biotherapeutics Inc. Stock Analysis and ForecastExponential return rates - jammulinksnews.com
Is Arcutis Biotherapeutics Inc. a good long term investmentFree Capital Growth Strategies - jammulinksnews.com
What drives Arcutis Biotherapeutics Inc. stock priceAccelerated wealth building - jammulinksnews.com
Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth - Investing.com India
(ARQT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st
Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada
Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN
FDA News and Decisions: Midyear Updates - Dermatology Times
Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN
(ARQT) Investment Analysis - news.stocktradersdaily.com
Arcutis Biotherapeutics - WBFF
Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria
Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis - Contemporary Pediatrics
Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus
ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis - Stock Titan
Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha
10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Australia
Arcutis Biotherapeutics Inc (ARQT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):